SAN DIEGO, Oct. 30, 2025 (GLOBE NEWSWIRE) -- Artiva Biotherapeutics, Inc. (Nasdaq: ARTV), a clinical-stage biotechnology company whose mission is to develop effective, safe, and accessible cell therapies for patients with devastating autoimmune diseases and cancers, announced today that management will participate at the following investor conferences: TD Cowen's Immunology & Inflammation Summit (Virtual) - fireside chat on Wednesday, November 12, 2025, at 11:30 a.m. ET 2025 Jefferies Global Healthcare Conf ...

Los Angeles, CA, Oct. 01, 2025 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (“ImmixBio”, “Company”, “We” or “Us” or ”IMMX”), a clinical-stage biopharmaceutical company developing cell therapies for AL Amyloidosis and other serious diseases, today announced that it will present and host institutional investor meetings at the 37th Annual Piper Sandler Healthcare Conference being held on December 2-4, 2025 at the Lotte New York Palace Hotel in New York, NY. The Company will be available for one-on-one meetings du ...

Core Viewpoint - Ernexa Therapeutics is an innovator in developing novel cell therapies for advanced cancer and autoimmune diseases, and will present at the H.C. Wainwright 27th Annual Global Investment Conference from September 8-10, 2025 [1][5]. Company Overview - Ernexa Therapeutics (NASDAQ: ERNA) focuses on engineering induced pluripotent stem cells (iPSCs) into induced mesenchymal stem cells (iMSCs) for scalable, off-the-shelf treatments without the need for patient-specific cell harvesting [6]. - The company is advancing two lead programs: ERNA-101, aimed at stimulating immune response against ovarian cancer, and ERNA-201, which targets inflammation to treat autoimmune diseases [4][7]. Presentation Details - Sanjeev Luther, President and CEO, along with Robert Pierce, M.D., Chief Scientific Officer, will provide an overview of the company's business, recent milestones, and pipeline during the conference [3]. - The presentation will emphasize Ernexa's proprietary iMSC platform, which enables scalable cell therapies for cancer and autoimmune diseases [3]. Future Outlook - The company aims to advance ERNA-101 toward clinical trials by 2026, highlighting its potential to change treatment paradigms for cancer and autoimmune diseases [5].

Core Insights - Alpha Teknova, Inc. has partnered with Pluristyx, Inc. to exclusively distribute the PluriFreeze™ cryopreservation system, enhancing the development of cell therapies [1][2] - The PluriFreeze system is designed to streamline the commercialization of allogeneic cell therapies, featuring a synthetic and animal-origin-free formulation [2][3] Company Overview - Teknova specializes in producing critical reagents for the life sciences sector, focusing on novel therapies, vaccines, and molecular diagnostics since 1996 [5] - Pluristyx is a biotechnology company that provides a range of products and services for cell and gene therapy development, including induced Pluripotent Stem Cells (iPSCs) [6] Product Details - The PluriFreeze system includes PluriFreeze Base, a cellular wash that mimics intracellular space, and PluriFreeze PF10, a low viscosity freezing medium with 10% DMSO [2][3] - Research-grade pricing for PluriFreeze Base starts at $240 per 100 mL, while PluriFreeze PF10 starts at $260 per 100 mL [3] Collaboration Benefits - The collaboration allows for better control and optimization of biopreservation conditions, facilitating the scaling of cell therapy development [3] - Customers can access both RUO and GMP-grade versions of the PluriFreeze products, with options for custom formulations [3]